cyclosporin + tacalcitol

Cyclosporin + tacalcitol is a combination therapy consisting of cyclosporin, an oral immunosuppressant, and tacalcitol, a topical vitamin D3 analog. Cyclosporin acts as a calcineurin inhibitor that suppresses T cell activation by inhibiting the phosphatase activity of calcineurin, thereby reducing the production of pro-inflammatory cytokines such as IL-2. Tacalcitol works by binding to vitamin D receptors in keratinocytes, modulating cell proliferation and differentiation. This combination has been investigated for use in dermatological conditions such as psoriasis, where cyclosporin provides systemic immunosuppression and tacalcitol offers local anti-proliferative effects on skin lesions[1]. The rationale for this regimen is to enhance efficacy while potentially minimizing the dose-dependent adverse effects associated with each agent.